Scilex Holding (SCLX) Profit After Tax (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Profit After Tax of -$45.6 million for Q1 2026, down 75.04% year-over-year from -$182.9 million in Q1 2025, and up 0.99% quarter-over-quarter from -$46.1 million in Q4 2025.
Scilex Holding (SCLX) Profit After Tax (2020 - 2026) Analysis & Trends
Scilex Holding's Profit After Tax history runs 7 years deep, the most recent figure standing at -$45.6 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 75.04% year-over-year to -$45.6 million; the TTM figure through Mar 2026 stood at -$393.0 million (down 476.36% YoY), while the FY2025 annual figure was -$374.1 million, down 462.57% from the prior year.
- Profit After Tax for Q1 2026 stood at -$45.6 million, up from -$46.1 million in the prior quarter.
- The five-year high for Profit After Tax was $21.5 million in Q3 2022, with the low at -$257.2 million in Q3 2025.
- The 5-year median for Profit After Tax is -$26.1 million (2025), against an average of -$36.7 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax jumped 1588.63% in 2022, then plunged 32141.26% in 2025.
- Scilex Holding's Profit After Tax stood at -$17.9 million in 2022, then dropped by 19.66% to -$21.4 million in 2023, then soared by 99.33% to -$143000.0 in 2024, then slumped by 32141.26% to -$46.1 million in 2025, then grew by 0.99% to -$45.6 million in 2026.
- Business Quant data shows SCLX's Profit After Tax at -$45.6 million in Q1 2026, -$46.1 million in Q4 2025, and -$257.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -248.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -114.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.65 Mn |
| Dec 31, 2025 | -46.11 Mn |
| Sep 30, 2025 | -257.23 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -26.08 Mn |
| Dec 31, 2024 | -143,000.00 |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Mar 31, 2024 | -24.38 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -30.75 Mn |
| Dec 31, 2022 | -17.88 Mn |
| Sep 30, 2022 | 21.50 Mn |
| Jun 30, 2022 | -17.84 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | -88.07 Mn |
| Sep 30, 2021 | -1.44 Mn |
| Jun 30, 2021 | -233,749.00 |